Trending...
- Ryan J. Murphy Named as 2026 Irish Legal 100 Honoree
- Gahl Sasson Releases "Agents of Chaos & Angels of Change: The Astrology of 2027
- The Truth Makers: The Quantum Lie Turns a Presidential Bribery Video Into a Crisis of Reality
RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics ("Aclipse" or "the Company"), a private biopharmaceutical company, today announced that the Company and its collaborator, The Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield in the United Kingdom (UK), were awarded a drug development research grant of £1.6 million (approximately US $2.2 million) from the UK's Medical Research Council (MRC), one of the largest funders of medical research worldwide, to support the translational development of M102. M102 is Aclipse's drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also referred to as motor neuron disease (MND) or Lou Gehrig's disease.
M102 is a potentially disease-modifying drug candidate that has shown promise to impede ALS disease progression in a wide array of preclinical models. Currently, there is no cure for ALS and there are no effective treatments to halt or slow the progression of the disease.
"This development funding from MRC is wonderful news for ALS/MND patients who are in dire need of an effective therapy to address this life-threatening neurodegenerative disease," stated Professor Dame Pamela Shaw, M.D., Director of SITraN and a primary contributor to M102's development program. "Along with my SITraN colleagues, Dr. Richard Mead and Dr. Laura Ferraiuolo, we spearheaded the ALS/MND biology research that led to the development of M102, including the discovery of a potential precision medicine approach for M102 in ALS/MND, so we are very appreciative of MRC's funding support."
Aclipse is taking a multiple biological pathway, multiple disease mechanism approach to ALS. M102 activates the NRF2 (nuclear factor erythroid 2-related factor 2) and HSF1 (Heat shock factor 1) signaling pathways, which are recently understood to impact ALS pathophysiology. M102 is expected to be mechanistically superior to currently available drugs and may lead to significant slowing of disease progression in both familial and sporadic ALS.
More on The PennZone
The MRC grant will also support the development of patient stratification biomarkers that will be applied in the M102 clinical studies, potentially enabling a personalized medicine approach in ALS. The goal of the patient stratification biomarkers is to identify M102 drug responders versus non-responders in order to target M102 to those ALS patients most likely to benefit from the drug.
"We greatly appreciate the support from MRC for our novel and broad multi-disease patho-mechanism approach to treating ALS patients," said Raymond K. Houck, CEO of Aclipse Therapeutics. "The MRC award, coupled with our recent FightMND grant award, accelerates M102's development into its first-in-human clinical studies and validates M102's biology and potential for a precision medicine approach for the treatment of ALS."
"The research funding from these programs will be key as they will support the completion of our investigational new drug (IND)-enabling work and the regulatory filings for first-in-human studies. Importantly, M102 may have applications in a wide array of conditions associated with impaired neuronal function such as Friedreich's ataxia, Huntington's disease and Parkinson's disease," added Mr. Houck.
About ALS/MND
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, is a progressive neurodegenerative disease that affects motor neurons (nerve cells) in the brain and the spinal cord. Eventually, people with ALS lose the ability to initiate and control muscle movement, which often leads to total paralysis and death within two to five years of diagnosis. There is no cure and limited life-prolonging treatments for the disease. Based on U.S. population studies, approximately 5,600 people in the U.S. are diagnosed with ALS each year and as many as 25,000 Americans have the disease at any given time.
About Medical Research Counsel
More on The PennZone
The United Kingdom's Medical Research Counsel's mission is to improve human health through world-class medical research. To achieve this, MRC supports research across the biomedical spectrum, from fundamental lab-based science to clinical trials, and in all major disease areas. MRC works closely with the UK's National Health Service and the UK Health Departments to deliver its mission and give a high priority to research that is likely to make a real difference to clinical practice and the health of the population.
About the Sheffield Institute for Translational Neuroscience
The Sheffield Institute for Translational Neuroscience (SITraN) is an international center of excellence recognized for its ground-breaking work in the fight against motor neurone disease and other common neurodegenerative disorders. SITraN brings together 300 staff and research students in multi-disciplinary teams with state-of-the-art laboratories and equipment to study neurological illness. The center is unique in its design to unite clinicians and multidisciplinary teams of scientists to translate discoveries in basic neuroscience into benefits for patients. The SITraN teams have developed a robust portfolio of in vitro and in vivo models to facilitate our understanding of disease mechanisms and identify new targets for therapeutic intervention which can be tested in our BRC experimental medicine programs.
The work of SITraN is a major pillar of the University of Sheffield's cross-faculty Neuroscience Institute, one of four flagship research institutes launched in 2019 to tackle the biggest global challenges through pioneering real-world solutions and involving >120 principal investigators in the Faculties of Medicine, Science and Engineering.
About Aclipse Therapeutics
Aclipse Therapeutics develops novel and differentiated drugs to treat orphan diseases with significant unmet medical needs. Our lead drug candidate, M102, is in development for the treatment of ALS with potential use in other neurodegenerative diseases such as Friedreich's ataxia, Huntington's disease and Parkinson's disease. M102 targets multiple disease pathomechanisms and enables a precision medicine approach for the identification of patients who are most likely to benefit from the drug. Aclipse has a very experienced orphan drug management team and a clinical advisory board of the top ALS physicians in the world. For more information about Aclipse, visit the website at https://www.aclipsetherapeutics.com or email info@aclipsetherapeutics.com.
M102 is a potentially disease-modifying drug candidate that has shown promise to impede ALS disease progression in a wide array of preclinical models. Currently, there is no cure for ALS and there are no effective treatments to halt or slow the progression of the disease.
"This development funding from MRC is wonderful news for ALS/MND patients who are in dire need of an effective therapy to address this life-threatening neurodegenerative disease," stated Professor Dame Pamela Shaw, M.D., Director of SITraN and a primary contributor to M102's development program. "Along with my SITraN colleagues, Dr. Richard Mead and Dr. Laura Ferraiuolo, we spearheaded the ALS/MND biology research that led to the development of M102, including the discovery of a potential precision medicine approach for M102 in ALS/MND, so we are very appreciative of MRC's funding support."
Aclipse is taking a multiple biological pathway, multiple disease mechanism approach to ALS. M102 activates the NRF2 (nuclear factor erythroid 2-related factor 2) and HSF1 (Heat shock factor 1) signaling pathways, which are recently understood to impact ALS pathophysiology. M102 is expected to be mechanistically superior to currently available drugs and may lead to significant slowing of disease progression in both familial and sporadic ALS.
More on The PennZone
- Atlanta Company Launches Free, Ad-Free, Nonpartisan Voter Planning App for All 50 States Ahead of the Nov. 3 Election
- Pastor Carlton L. Aiken Sr. Celebrates 55 Years with "Sermonic Selections"
- J. Wes Seeks Jazz Musicians, Vocalists and Bands for Philadelphia Live Music Event
- NECP Promotes Chertova to Senior Business Analyst
- Security Industry Veteran Anthony Rumore Launches AegisLead to Help Security Companies Find Business and Manage Growth
The MRC grant will also support the development of patient stratification biomarkers that will be applied in the M102 clinical studies, potentially enabling a personalized medicine approach in ALS. The goal of the patient stratification biomarkers is to identify M102 drug responders versus non-responders in order to target M102 to those ALS patients most likely to benefit from the drug.
"We greatly appreciate the support from MRC for our novel and broad multi-disease patho-mechanism approach to treating ALS patients," said Raymond K. Houck, CEO of Aclipse Therapeutics. "The MRC award, coupled with our recent FightMND grant award, accelerates M102's development into its first-in-human clinical studies and validates M102's biology and potential for a precision medicine approach for the treatment of ALS."
"The research funding from these programs will be key as they will support the completion of our investigational new drug (IND)-enabling work and the regulatory filings for first-in-human studies. Importantly, M102 may have applications in a wide array of conditions associated with impaired neuronal function such as Friedreich's ataxia, Huntington's disease and Parkinson's disease," added Mr. Houck.
About ALS/MND
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, is a progressive neurodegenerative disease that affects motor neurons (nerve cells) in the brain and the spinal cord. Eventually, people with ALS lose the ability to initiate and control muscle movement, which often leads to total paralysis and death within two to five years of diagnosis. There is no cure and limited life-prolonging treatments for the disease. Based on U.S. population studies, approximately 5,600 people in the U.S. are diagnosed with ALS each year and as many as 25,000 Americans have the disease at any given time.
About Medical Research Counsel
More on The PennZone
- Charlie Shaw and Patrick Carragher win SEO Agency of the Year 2026
- Canadian Woman Plants 1,667 Love Stories in a Field of Peonies That Could Bloom for 100 Years
- New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
- Beyond the Odds: BetQL Combines Sharp Money Trends and Real Time Odds to Help Bettors Find Value
- Mark Schork and Terri Smith Honored by Philadelphia Bar Association as 'Bar Stars'
The United Kingdom's Medical Research Counsel's mission is to improve human health through world-class medical research. To achieve this, MRC supports research across the biomedical spectrum, from fundamental lab-based science to clinical trials, and in all major disease areas. MRC works closely with the UK's National Health Service and the UK Health Departments to deliver its mission and give a high priority to research that is likely to make a real difference to clinical practice and the health of the population.
About the Sheffield Institute for Translational Neuroscience
The Sheffield Institute for Translational Neuroscience (SITraN) is an international center of excellence recognized for its ground-breaking work in the fight against motor neurone disease and other common neurodegenerative disorders. SITraN brings together 300 staff and research students in multi-disciplinary teams with state-of-the-art laboratories and equipment to study neurological illness. The center is unique in its design to unite clinicians and multidisciplinary teams of scientists to translate discoveries in basic neuroscience into benefits for patients. The SITraN teams have developed a robust portfolio of in vitro and in vivo models to facilitate our understanding of disease mechanisms and identify new targets for therapeutic intervention which can be tested in our BRC experimental medicine programs.
The work of SITraN is a major pillar of the University of Sheffield's cross-faculty Neuroscience Institute, one of four flagship research institutes launched in 2019 to tackle the biggest global challenges through pioneering real-world solutions and involving >120 principal investigators in the Faculties of Medicine, Science and Engineering.
About Aclipse Therapeutics
Aclipse Therapeutics develops novel and differentiated drugs to treat orphan diseases with significant unmet medical needs. Our lead drug candidate, M102, is in development for the treatment of ALS with potential use in other neurodegenerative diseases such as Friedreich's ataxia, Huntington's disease and Parkinson's disease. M102 targets multiple disease pathomechanisms and enables a precision medicine approach for the identification of patients who are most likely to benefit from the drug. Aclipse has a very experienced orphan drug management team and a clinical advisory board of the top ALS physicians in the world. For more information about Aclipse, visit the website at https://www.aclipsetherapeutics.com or email info@aclipsetherapeutics.com.
0 Comments
Latest on The PennZone
- EMBER™ Unveils the Workplace Identity Score™ (WIS™), the First Standard for Measuring Workplace Impact on Workforce Performance & Business Growth
- With Oil Prices Surging…Sky Quarry's Nevada Refinery Is Back in Action — CEO Highlights a Powerful New Growth Chapter for (N A S D A Q: SKYQ)
- Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Win Gold in Raleigh's Best Awards for Second Consecutive Year
- We are Talker Study: 64% of AI Users Have Bought From a Brand AI Introduced, as The Invisible Shortlist Reshapes Brand Discovery
- One in three Americans may have lost track of retirement savings from a previous job
- Political Concerns Drive US Investors to Golden Visas
- The Truth Makers: The Quantum Lie Turns a Presidential Bribery Video Into a Crisis of Reality
- 2027 Health Insurance Open Enrollment
- Ryan J. Murphy Named as 2026 Irish Legal 100 Honoree
- Gahl Sasson Releases "Agents of Chaos & Angels of Change: The Astrology of 2027
- Joe "LIL Snuff" Perri Takes Center Stage as SMACK Fighting Championships 2 Returns to Philly
- Tek84 Unveils New Brand Identity Built to Magnify What Security Officers Can Do
- CoreVar Announces Cooking with AI, an Eight-Topic Live Webinar Series
- Mr Hospital Bed Cites Hill Rom Hospital Bed Models Best Value Home Care Hospital Beds 2026
- Dr. Lynn Peterson Releases Food: The Final Frontier on Food and Chronic Disease
- Tucker Chiropractic Center Highlights a Root-Cause Approach to Pain Relief & Wellness
- WOWX labs Closes US$10 Million Founder-Led Growth Financing as WOWX.market Enters Scale Phase
- BESTBUYSTORE opens its dropshipping model to independent merchants
- America's Hometown Thanksgiving Parade in Plymouth, MA, on Saturday, November 21, 2026
- Navigating a Changing Market: How AIX Group Is Responding to a Challenging Year